Roche extends research contracts with Evotec

By E. Janene Geiss

Philadelphia, April 25 - Evotec AG announced Tuesday that it signed two significant service contracts with Roche. The contracts extend the global medicinal chemistry agreement signed in May 2004 for a further 12 months and the medicinal chemistry collaboration in oncology, signed in October 2003, for an additional two years, according to a company news release.

In the global medicinal chemistry agreement, a dedicated team of chemists from Evotec supports all of Roche's European and U.S. research sites in the design and synthesis of high-quality compounds for lead finding and optimization programs, according to a company news release.

In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche's oncology research, officials said.

No financial details were released.

Evotec is a Hamburg, Germany, biopharmaceutical company that develops small molecule-based drugs.

Roche is a Basel, Switzerland, pharmaceutical and health care products company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.